Gustave Roussy, Cancer Campus, Grand Paris
Quick facts
Marketed products
- rhTSH · Oncology; Endocrinology
rhTSH (recombinant human thyroid-stimulating hormone) stimulates the thyroid gland to produce and release thyroid hormones. - Vistide · Immunology
Phase 3 pipeline
- doxorubicin, ifosfamide, cisplatin · Oncology
Doxorubicin, ifosfamide, and cisplatin work by interfering with DNA replication and function, leading to cell death in rapidly dividing cancer cells. - Doxorubicin, Methotrexate · Oncology
This combination uses doxorubicin to intercalate DNA and inhibit topoisomerase II, while methotrexate inhibits dihydrofolate reductase to disrupt nucleotide synthesis, together producing synergistic cytotoxic effects against cancer cells. - DS-1062a · Oncology
DS-1062a is an antibody-drug conjugate that targets TROP-2 on cancer cells and delivers a topoisomerase I inhibitor payload to induce cell death. - Etoposide, Ifosfamide, Methotrexate · Oncology
This is a combination chemotherapy regimen that kills cancer cells by damaging DNA and preventing cell division through multiple mechanisms. - Genomic driven chemotherapy · Oncology
Genomic-driven chemotherapy selects and administers chemotherapy agents based on individual tumor genomic profiling to optimize treatment efficacy and reduce toxicity. - half cyclophosphamide · Oncology
Half-dose cyclophosphamide is a reduced-intensity alkylating agent that cross-links DNA to kill rapidly dividing cells, particularly in cancer and autoimmune contexts. - I131 · Oncology
Iodine-131 is a radioactive isotope that emits beta particles to destroy thyroid cancer cells and other iodine-avid malignancies. - Isolated pelvis perfusion · Oncology
Isolated pelvic perfusion delivers high-dose chemotherapy directly to pelvic tumors while minimizing systemic exposure through regional vascular isolation. - LMB B · Oncology
LMB-B is an immunotoxin that targets CD25-expressing cells by delivering a toxin payload to eliminate malignant T cells. - LMB C · Oncology
LMB-C is an immunotoxin that targets CD25-expressing cells by delivering a toxin payload to eliminate malignant T cells. - mini CYVE, without 3 maintenance courses · Oncology
mini CYVE targets the CD47/SIRPα axis to promote phagocytosis of cancer cells. - rhTSH stimulation · Oncology
Recombinant human thyroid-stimulating hormone (rhTSH) stimulates thyroid hormone production and uptake to enhance radioactive iodine accumulation in thyroid cancer cells. - Thromboprophylaxis · Cardiovascular
- without COPADM3
This drug targets the PD-1 receptor to inhibit cancer cell growth.
Phase 2 pipeline
- Anti-PD-L1 antibody atezolizumab · Oncology
Atezolizumab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer. - ASP3082 · Oncology
ASP3082 is an investigational drug with unknown mechanism of action. - CDDP, 5 Fu
- Dex2
- Etoposide, carboplatin, melphalan, cisplatin, thiotepa · Oncology
Etoposide, carboplatin, melphalan, cisplatin, and thiotepa are chemotherapeutic agents that work by interfering with DNA replication and cell division, ultimately leading to cell death. - Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab
- gemcitabine, ifosfamide, cisplatin, G-CSF
- Gemox, Cetuximab
- MaaT033 capsule
- Oxaliplatin IV
- Pembrolizumab adjuvant
- Temozolomide, Cisplatinum
- Vinorelbine, cyclofosfamide
Phase 1 pipeline
- biopsy liquid
- Dose-dense regimen
- Fadraciclib · Other
- HPVDC injection level dose 1
- Ipilimumab IT
- Ipilimumab IV
- LY2780301
- Nivolumab IV
- Peposertib · Other
- regorafenib tablet
- Solid tumor and CT DNA
- Topotecan, Temozolomide
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI brief
- Gustave Roussy, Cancer Campus, Grand Paris pipeline updates RSS
Frequently asked questions about Gustave Roussy, Cancer Campus, Grand Paris
What are Gustave Roussy, Cancer Campus, Grand Paris's marketed drugs?
Top marketed products include rhTSH, Vistide.
What is Gustave Roussy, Cancer Campus, Grand Paris's pipeline?
Gustave Roussy, Cancer Campus, Grand Paris has 14 drugs in Phase 3, 13 in Phase 2, 12 in Phase 1. Late-stage candidates include doxorubicin, ifosfamide, cisplatin, Doxorubicin, Methotrexate, DS-1062a, Etoposide, Ifosfamide, Methotrexate.
Related
- rhTSH · Oncology; Endocrinology
- Vistide · Immunology
- Sector hub: All tracked pharma companies